Company intelligence / Profile preview

Aoxing Pharmaceutical Company, Inc.

Shijiazhuang, Hebei Province, Chinasec.gov ↗

Ownership: Private
Employees: ~500
Development stage: Commercial

Overview

The company has received approval for Tilidine in China (February 2019) and has conducted clinical trials for Codeine Phosphate Compound Medicine for cold and flu treatment. They also received approval for an injectable drug for treating Ischemic Cerebrovascular Disease in December 2008.

Therapeutic areas: NeurologyInfectious Diseases
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

1 asset

Zhongtong'an

Unknown

Partnerships

QRxPharma Pty Ltd. (strategic alliance for development of MoxDuo IV)

Beyond the preview

Go deeper on Aoxing Pharmaceutical Company, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aoxing Pharmaceutical Company, Inc..

Explore the full profile